

## **Delivering Innovative Medical Products to Patients in China** **The Third Public-private delegation from Japan meet high-level officials in Beijing, China.**

Yasuhiro Suzuki, Vice-Minister for Health, MHLW, Dr. Kondo, Chief Executives of PMDA, Haruo Naito, CEO of Eisai and Yoshihiko Hatanaka, Chairman of Board of Astellas led the third delegation from Japan to discuss healthcare and regulatory affairs issues with high-level Chinese officials in early December 2018. On the Chinese government side were officials from the National Medical Products Administration (NMPA), National Health Commission (NHC) and the National Medical Security Administration (NMSA). It is the third year that such mission was held, marking the strong commitment of public-private collaboration in healthcare.

Discussions with Deputy Director of the National Medical Products Administration (NMPA) Xu Jinghe centered on the pharmaceutical regulatory environment. Xu highlighted the significant achievement of the past engagements that led to a commitment of collaborations for the health of both countries. NMPA and MHLW had also jointly hosted a regulatory conference on the morning of 5th where both authorities shared the latest regulatory development and the ongoing ICH initiatives with the industry participants. Thanks to the devotion and hard work of NMPA in the past few years, NMPA significantly reduced the drug application backlog from over 22,000 in 2015 to less than 3,000 today, reducing review timeline from five to six years to less than a year for some innovative medicines.



This year was the first year for the mission to visit the newly established National Medical Security Administration (NMSA). Deputy Director Shi Zihai welcomed the Japan public-private representatives and shared the latest initiatives of accelerating reimbursement for innovative medicines for Chinese patients such as the national level drug price negotiation and timely update of National drug reimbursement list. Centralized drug procurement platform is also being established to better enhance the efficiency at the hospital level. The mission welcomed the administration's dedication that brought early access to life-saving medicines in China.

Both parties agreed to continue sharing experiences in the field of medical security in the coming years.



Last but not least, the mission met with Vice Minister, Cui Li, National Health Commission, NHC to discuss health and elderly care strategy. Cui Li shared the roadmap to achieve the Healthy 2030 Vision and the approach for solving challenges as the rapidly aging society. Japan has the highest rate of elderly and the highest life expectancy of any country while China is now home to an elderly population that is bigger than the entire population of Japan. Both countries have committed to enhance experience sharing to tackle such kind of shared challenges.

The mission further strengthened the ties between the two governments and public-private partnerships. JPMA believes that only through continuous efforts can we truly achieve our shared goal - delivering innovative, high-quality medicines for the patients in China.

END